Ceftazidime: Third-Generation Cephalosporin for Pseudomonas Research

Executive Summary: Ceftazidime is a potent third-generation cephalosporin antibiotic notable for high activity against Gram-negative bacteria, especially Pseudomonas aeruginosa (APExBIO). It resists hydrolysis by most β-lactamases, which enables its use against β-lactamase-producing Enterobacteriaceae (Tcephydrochloride resource). Its mechanism involves inhibition of bacterial cell wall synthesis, leading to bactericidal effects. Ceftazidime is widely used in research and clinical settings for bacterial pneumonia and bronchitis caused by susceptible organisms. The compound's storage, solubility, and dosing parameters are well defined and facilitate reproducible experimental design.

Biological Rationale

Ceftazidime, chemically designated as C₂₂H₂₂N₆O₇S₂ with a molecular weight of 546.58, is a third-generation cephalosporin antibiotic (APExBIO). It is optimized for broad-spectrum in vitro activity against both Gram-positive and Gram-negative aerobic bacteria, with particular potency against Pseudomonas aeruginosa (Tcephydrochloride article). Ceftazidime is resistant to hydrolysis by common β-lactamases, enzymes frequently implicated in antimicrobial resistance among Enterobacteriaceae (Doripenemhydrate review). This resistance is especially critical as carbapenem-resistant Enterobacter cloacae and other Gram-negative pathogens have shown increasing prevalence and multidrug resistance, complicating therapy options (Chen et al., 2025).

Mechanism of Action of Ceftazidime

Ceftazidime acts by binding to penicillin-binding proteins (PBPs) on the bacterial cell wall, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis (Gestrinonesource summary). This disruption leads to cell lysis and death in susceptible bacteria. Its high affinity for PBPs in Gram-negative bacteria, such as P. aeruginosa, accounts for its effectiveness. Ceftazidime’s structural modifications confer notable resistance to hydrolysis by extended-spectrum β-lactamases (ESBLs), making it a valuable tool in the study and treatment of β-lactamase-producing organisms.

Evidence & Benchmarks

• Ceftazidime demonstrates superior activity against Pseudomonas aeruginosa compared to other cephalosporins (https://tcephydrochloride.com/index.php?g=Wap&m=Article&a=detail&id=11056).
• It is highly resistant to hydrolysis by β-lactamases, enabling use against β-lactamase-producing Enterobacteriaceae strains (https://doripenemhydrate.com/index.php?g=Wap&m=Article&a=detail&id=15112).
• Clinical isolates of carbapenem-resistant Enterobacter cloacae frequently harbor β-lactamase genes, but ceftazidime/avibactam combinations retain higher activity than many alternatives (Chen et al., 2025).
• Ceftazidime is less active against Staphylococcus aureus compared to first- and second-generation cephalosporins (https://azosemidecompound.com/index.php?g=Wap&m=Article&a=detail&id=107).
• Typical research dosages range from 3–6 g/day in divided doses (2–4 times daily), with recommended storage at -20°C for both solid and solution forms (APExBIO).

Applications, Limits & Misconceptions

Ceftazidime is widely used in research and clinical protocols for the management of bacterial pneumonia, bronchitis, and other infections caused by susceptible Gram-negative pathogens. Its robust β-lactamase resistance profile makes it valuable in studies of multidrug-resistant organisms, particularly in respiratory medicine and hospital-acquired infections. The B3539 kit from APExBIO is frequently referenced for in vitro research applications owing to its stability and defined solubility parameters (Ceftazidime product page).

This article extends the analysis found in "Ceftazidime: Third-Generation Cephalosporin Targeting Pse..." by providing updated resistance benchmarks and workflow considerations specific to recent multidrug-resistant Enterobacteriaceae trends. For a review of ceftazidime’s clinical spectrum, see "Ceftazidime: Third-Generation Cephalosporin for Gram-Nega...", which this piece updates with post-pandemic resistance data. Mechanistic nuances, especially regarding β-lactamase resistance, are further detailed compared to "Ceftazidime: Advanced Insights into β-Lactamase Resistanc...".

Common Pitfalls or Misconceptions

• Ineffectiveness against non-susceptible Gram-positive cocci: Ceftazidime is less potent against Staphylococcus aureus compared to earlier generation cephalosporins.
• Not universally resistant to all β-lactamases: Some ESBL- or carbapenemase-producing strains may still exhibit resistance despite ceftazidime's design.
• Solubility limitations: Ceftazidime is insoluble in water and ethanol; DMSO (≥21.25 mg/mL) is required for stock solutions.
• Stability concerns: Stock solutions must be stored below -20°C and used promptly due to degradation at ambient conditions.
• Resistance emergence: Prolonged or inappropriate use can select for resistant subpopulations, especially in hospital settings.

Workflow Integration & Parameters

Ceftazidime is supplied as a solid compound and should be dissolved in DMSO at concentrations ≥21.25 mg/mL for experimental use. It is insoluble in water and ethanol. For optimal stability, store both powder and solution below -20°C and protect from light. Recommended working concentrations and dosing regimens in animal models or in vitro studies typically range from 3 to 6 g/day, divided into 2 to 4 doses per day. Prompt use after solution preparation is advised to maintain activity (APExBIO).

Conclusion & Outlook

Ceftazidime remains a mainstay in research and clinical management of Gram-negative, β-lactamase-producing bacterial infections, especially those involving Pseudomonas aeruginosa. New studies highlight the ongoing threat of multidrug-resistant Enterobacteriaceae, underscoring the importance of robust, validated tools like ceftazidime for both basic research and translational science (Chen et al., 2025). APExBIO's B3539 ceftazidime product offers well-characterized quality and workflow integration for modern microbiological research.